Wegov disease - Symptoms, Causes, Treatment & Prevention

📅 Updated: April 2026 ⏱️ 6 min read ✅ Medically reviewed
```html Granulomatosis with Polyangiitis (Wegener’s Disease) – Complete Guide

Granulomatosis with Polyangiitis (formerly Wegener’s Disease)

Overview

Granulomatosis with polyangiitis (GPA) is a rare, chronic autoimmune disease that causes inflammation of small‑ and medium‑sized blood vessels (vasculitis). The inflammation can lead to granuloma formation—clusters of immune cells—that damage the nasal passages, lungs, kidneys, and other organs.

  • Who it affects: Adults most commonly, with a slight male predominance. Median onset is 40–55 years, but children and older adults can be affected.
  • Prevalence: Approximately 3 cases per 100,000 people in the United States and Europe; incidence is 1–2 cases per million per year.[1][2]
  • Geography: Uniform worldwide distribution; slightly higher rates in northern Europe and North America.

Symptoms

Because GPA can involve many organ systems, symptoms are often variable. Early recognition is key.

Upper Respiratory Tract

  • Chronic sinusitis – facial pressure, nasal discharge, or congestion that does not improve with usual treatments.
  • Nasal ulceration or crusting – may cause nosebleeds (epistaxis).
  • Otitis media – ear pain or hearing loss.
  • Ear, nose, and throat (ENT) granulomas – can lead to saddle‑nose deformity.

Lower Respiratory Tract

  • Cough – often dry, but can become productive with blood‑tinged sputum.
  • Shortness of breath – especially during exertion.
  • Hemoptysis – coughing up blood (requires urgent evaluation).
  • Chest pain – pleuritic in nature.

Renal (Kidney) Manifestations

  • Hematuria – blood in urine, sometimes visible.
  • Proteinuria – foamy urine.
  • Rapidly progressive glomerulonephritis – can cause sudden loss of kidney function.

Systemic Symptoms

  • Fever, night sweats, unexplained weight loss.
  • Fatigue and general malaise.
  • Joint pain (arthralgia) without swelling.
  • Skin lesions – palpable purpura, ulcerations, or livedo reticularis.

Rare Involvement

  • Eye inflammation (scleritis, uveitis).
  • Peripheral nervous system – mononeuritis multiplex.
  • Cardiac involvement – pericarditis or myocarditis.

Causes and Risk Factors

GPA is an autoimmune disease; the exact trigger is unknown, but several mechanisms have been identified.

Immunologic Factors

  • ANCA antibodies – especially anti‑proteinase 3 (c‑ANCA) antibodies are present in 80–90 % of active cases.[3]
  • Disordered neutrophil activation leading to vessel wall damage.

Genetic Predisposition

  • HLA‑DPB1*04 and HLA‑DRB1*15 alleles confer modest increased risk.
  • Family clustering is rare but documented.

Environmental Triggers

  • Silica dust exposure (e.g., mining, construction) is associated with a 2‑3‑fold higher risk.[4]
  • Chronic infections (e.g., Staphylococcus aureus nasal carriage) may act as a “second hit.”

Other Risk Modifiers

  • Smoking – doubles the likelihood of pulmonary involvement.
  • Age 40‑60 years – highest incidence.

Diagnosis

Diagnosing GPA requires a combination of clinical suspicion, laboratory testing, imaging, and often tissue biopsy.

Laboratory Tests

  • c‑ANCA (anti‑proteinase 3) assay – positive in ~80 % of active disease; helps confirm suspicion.
  • Complete blood count (CBC) – may show anemia or leukocytosis.
  • Renal panel – serum creatinine, BUN, urinalysis for hematuria/proteinuria.
  • Erythrocyte sedimentation rate (ESR) / C‑reactive protein (CRP) – markers of systemic inflammation.

Imaging

  • Chest X‑ray or CT scan – reveals nodules, cavitary lesions, or infiltrates.
  • Sinus CT – shows mucosal thickening, bony erosions.
  • Chest CT is more sensitive for early lung disease.

Biopsy (Gold Standard)

  • Obtaining tissue from affected sites (nasal mucosa, lung nodule, kidney) demonstrates necrotizing granulomatous inflammation and vasculitis.
  • Kidney biopsy is crucial when rapid glomerulonephritis is suspected.

Classification Criteria (2022 ACR/EULAR)

Patients meeting ≥5 points (based on ANCA status, granulomatous involvement, and renal disease) are classified as having GPA.[5]

Treatment Options

Therapy aims to induce remission, then maintain it while minimizing drug toxicity.

Induction Therapy (rapid disease control)

  • Glucocorticoids – high‑dose oral prednisone (1 mg/kg/day) or IV methylprednisolone (500–1000 mg daily for 3 days) until symptoms improve.
  • Immunosuppressive agents:
    • Rituximab (anti‑CD20 monoclonal antibody) – 375 mg/m² weekly × 4 weeks or 1 g on days 1 and 15; now preferred over cyclophosphamide for many patients.[6]
    • Cyclophosphamide – oral (2 mg/kg/day) or IV (15 mg/kg every 2–3 weeks) for 3–6 months; used when rituximab contraindicated.
  • Adjunct plasmapheresis may be considered for severe renal or pulmonary hemorrhage.

Maintenance Therapy (prevent relapse)

  • Rituximab – 500 mg IV every 6 months for 2–5 years, or as per physician protocol.
  • Azathioprine – 2–2.5 mg/kg/day.
  • Mycophenolate mofetil – 1–1.5 g twice daily (alternative in patients intolerant to azathioprine).
  • Low‑dose prednisone (≤5 mg/day) is often continued for the first year of maintenance.

Supportive Care

  • Prophylactic antibiotics (e.g., trimethoprim‑sulfamethoxazole) to prevent Pneumocystis jirovecii pneumonia (PJP) and reduce S. aureus nasal carriage.
  • Vaccinations – influenza, pneumococcal, COVID‑19 (non‑live vaccines are safe).
  • Bone health – calcium, vitamin D, and bisphosphonates if on long‑term steroids.
  • Regular monitoring of blood counts, liver & kidney function, and ANCA titres.

Living with Granulomatosis with Polyangiitis

Managing GPA is a lifelong partnership between you, your rheumatologist, and other specialists.

Practical Daily Tips

  • Medication adherence – use pill organizers or phone reminders.
  • Track symptoms – keep a log of fever, cough, urinary changes, or new skin lesions.
  • Stay hydrated – helps kidney function.
  • Protect your lungs – avoid smoking and exposure to dust, fumes, or strong chemicals.
  • Skin care – gentle cleansers, moisturize to prevent cracks that could become infection portals.
  • Physical activity – low‑impact exercise (walking, swimming) improves stamina and bone density.
  • Regular follow‑up – labs every 1–3 months initially, then every 6 months once stable.

Psychosocial Support

  • Consider counseling or support groups (American College of Rheumatology, Vasculitis Foundation).
  • Inform employers and schools about your condition for reasonable accommodations.

Prevention

Because GPA’s exact cause is unknown, primary prevention is limited, but several steps can reduce risk of disease flare or complications.

  • Avoid known triggers – smoking cessation, minimize silica or metal dust exposure.
  • Prompt treatment of infections – especially chronic sinusitis or Staphylococcus aureus colonization.
  • Vaccinations – keep immunizations up to date before initiating immunosuppressive therapy.
  • Regular health screening – early detection of renal involvement via routine urinalysis.

Complications

If untreated or inadequately controlled, GPA can cause irreversible organ damage.

  • End‑stage renal disease (ESRD) – may require dialysis or transplantation.
  • Permanent lung fibrosis – leading to chronic respiratory insufficiency.
  • Severe infection – from immunosuppression (bacterial, viral, fungal).
  • Vascular aneurysms or thrombosis – rare but life‑threatening.
  • Secondary malignancies – long‑term cyclophosphamide increases bladder cancer risk.
  • Relapse – up to 30–50 % experience disease recurrence within 5 years.

When to Seek Emergency Care

Immediate medical attention is required if you experience any of the following:
  • Sudden, severe shortness of breath or chest pain.
  • Coughing up large amounts of blood (hemoptysis).
  • Rapidly worsening kidney function – marked decrease in urine output, swelling of legs or face.
  • Severe headache, vision changes, or neurological deficits (possible CNS involvement).
  • High fever (>101 °F / 38.5 °C) with chills and no clear source.
  • Signs of severe infection: rapidly spreading skin rash, intense abdominal pain, or unexplained confusion.
Call 911 or go to the nearest emergency department if any of these occur.

References

  1. G. P. Jennette et al., “2022 Revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides,” Arthritis & Rheumatology, 2022.
  2. U.S. Centers for Disease Control and Prevention. “Vasculitis: Granulomatosis with Polyangiitis.” Accessed March 2024.
  3. V. K. Scheinberg et al., “ANCA‑associated vasculitis: Pathogenesis and clinical significance,” New England Journal of Medicine, 2023.
  4. M. H. Górny et al., “Silica exposure and risk of ANCA‑associated vasculitis: A systematic review,” Occupational & Environmental Medicine, 2022.
  5. 2022 ACR/EULAR Classification Criteria for GPA, Arthritis & Rheumatology, 2022.
  6. J. P. Stone et al., “Rituximab versus Cyclophosphamide for ANCA‑Associated Vasculitis,” NEJM, 2010; updated guidelines 2023.
```

⚠️ Medical Disclaimer

Important: The information provided on this page is for general informational purposes only and is not intended as a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition.

If you think you may have a medical emergency, call your doctor, go to the emergency department, or call 911 immediately.

📚 Medical References